Name: Identificatie van PD-1/PD-L1-remmers met Surface Plasmon Resonance-technologie (Video) | JoVE Journal
Uploaded: 2025-05-02T13:30:00.000+00:00
Duration: 7 min 4 s
Description: Leer een blokkeringsassay voor PD-1/PD-L1-remmers met surface plasmon resonance-technologie. Deze methode ondersteunt high-throughput screening voor kankerimmunotherapie en versnelt de ontdekking van nieuwe geneesmiddelen.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

<ol><li>Ribas, A., Wolchok, J. D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Cancer+immunotherapy+using+checkpoint+blockade%5BTitle%5D)+AND+%22Science%22%5BJournal%5D)">Cancer immunotherapy using checkpoint blockade.</a> Science. 359 (6382), 1350-1355 (2018).</li>
<li>Zhang, X., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Structural+and+functional+analysis+of+the+costimulatory+receptor+programmed+death-1%5BTitle%5D)+AND+%22Immunity%22%5BJournal%5D)">Structural and functional analysis of the costimulatory receptor programmed death-1.</a> Immunity. 20 (3), 337-347 (2004).</li>
<li>Freeman, G. J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Engagement+of+the+PD-1+immunoinhibitory+receptor+by+a+novel+B7+family+member+leads+to+negative+regulation+of+lymphocyte+activation%5BTitle%5D)+AND+%22J+Exp+Med%22%5BJournal%5D)">Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.</a> J Exp Med. 192 (7), 1027-1034 (2000).</li>
<li>Han, Y., Liu, D., Li, L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((PD-1%2FPD-L1+pathway%3A+Current+researches+in+cancer%5BTitle%5D)+AND+%22Am+J+Cancer+Res%22%5BJournal%5D)">PD-1/PD-L1 pathway: Current researches in cancer.</a> Am J Cancer Res. 10 (3), 727-742 (2020).</li>
<li>Lyu, N., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Recognition+of+PDL1%2FL2+by+different+induced-fit+mechanisms+of+PD1%3A+A+comparative+study+of+molecular+dynamics+simulations%5BTitle%5D)+AND+%22Phys+Chem+Chem+Phys%22%5BJournal%5D)">Recognition of PDL1/L2 by different induced-fit mechanisms of PD1: A comparative study of molecular dynamics simulations.</a> Phys Chem Chem Phys. 22 (3), 1276-1287 (2020).</li>
<li>Taube, J. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Colocalization+of+inflammatory+response+with+B7-H1+expression+in+human+melanocytic+lesions+supports+an+adaptive+resistance+mechanism+of+immune+escape%5BTitle%5D)+AND+%22Sci+Trans+Med%22%5BJournal%5D)">Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape.</a> Sci Trans Med. 4 (127), 127ra37(2012).</li>
<li>Sun, X., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Immune-related+adverse+events+associated+with+programmed+cell+death+protein-1+and+programmed+cell+death+ligand+1+inhibitors+for+non-small+cell+lung+cancer%3A+A+PRISMA+systematic+review+and+meta-analysis%5BTitle%5D)+AND+%22BMC+Cancer%22%5BJournal%5D)">Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: A PRISMA systematic review and meta-analysis.</a> BMC Cancer. 19 (1), 558(2019).</li>
<li>Alkholifi, F. K., Alsaffar, R. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Dostarlimab+an+inhibitor+of+PD-1%2FPD-L1%3A+A+new+paradigm+for+the+treatment+of+cancer%5BTitle%5D)+AND+%22Medicina%22%5BJournal%5D)">Dostarlimab an inhibitor of PD-1/PD-L1: A new paradigm for the treatment of cancer.</a> Medicina. 58 (11), 1572(2022).</li>
<li>Uzar, W., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((An+updated+patent+review+on+PD-1%2FPD-L1+antagonists+%282022-present%29%5BTitle%5D)+AND+%22Expert+Opin+Ther+Pat%22%5BJournal%5D)">An updated patent review on PD-1/PD-L1 antagonists (2022-present).</a> Expert Opin Ther Pat. 34 (8), 627-650 (2024).</li>
<li>Ai, L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Research+status+and+outlook+of+PD-1%2FPD-L1+inhibitors+for+cancer+therapy%5BTitle%5D)+AND+%22Drug+Des+Devel+Ther%22%5BJournal%5D)">Research status and outlook of PD-1/PD-L1 inhibitors for cancer therapy.</a> Drug Des Devel Ther. 14, 3625-3649 (2020).</li>
<li>Conroy, M., Naidoo, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Immune-related+adverse+events+and+the+balancing+act+of+immunotherapy%5BTitle%5D)+AND+%22Nat+Commun%22%5BJournal%5D)">Immune-related adverse events and the balancing act of immunotherapy.</a> Nat Commun. 13 (1), 392(2022).</li>
<li>Guzik, K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Small-molecule+inhibitors+of+the+Programmed+Cell+Death-1%2FProgrammed+Death-Ligand+1+%28PD-1%2FPD-L1%29+interaction+via+transiently+induced+protein+states+and+dimerization+of+PD-L1%5BTitle%5D)+AND+%22J+Med+Chem%22%5BJournal%5D)">Small-molecule inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) interaction via transiently induced protein states and dimerization of PD-L1.</a> J Med Chem. 60 (13), 5857-5867 (2017).</li>
<li>Sifniotis, V., Cruz, E., Eroglu, B., Kayser, V. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Current+advancements+in+addressing+key+challenges+of+therapeutic+antibody+design%2C+manufacture%2C+and+formulation%5BTitle%5D)+AND+%22Antibodies%22%5BJournal%5D)">Current advancements in addressing key challenges of therapeutic antibody design, manufacture, and formulation.</a> Antibodies. 8 (2), 36(2019).</li>
<li>Beck, H., Härter, M., Haß, B., Schmeck, C., Baerfacker, L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Small+molecules+and+their+impact+in+drug+discovery%3A+A+perspective+on+the+occasion+of+the+125th+anniversary+of+the+Bayer+Chemical+Research+Laboratory%5BTitle%5D)+AND+%22Drug+Discov+Today%22%5BJournal%5D)">Small molecules and their impact in drug discovery: A perspective on the occasion of the 125th anniversary of the Bayer Chemical Research Laboratory.</a> Drug Discov Today. 27 (6), 1560-1574 (2022).</li>
<li>Nguyen, H. H., Park, J., Kang, S., Kim, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Surface+plasmon+resonance%3A+A+Versatile+technique+for+biosensor+applications%5BTitle%5D)+AND+%22Sensors+%28Basel%2C+Switzerland%29%22%5BJournal%5D)">Surface plasmon resonance: A Versatile technique for biosensor applications.</a> Sensors (Basel, Switzerland). 15 (5), 10481-10510 (2015).</li>
<li>Liu, C., Seeram, N. P., Ma, H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Small+molecule+inhibitors+against+PD-1%2FPD-L1+immune+checkpoints+and+current+methodologies+for+their+development%3A+A+review%5BTitle%5D)+AND+%22Cancer+Cell+Int%22%5BJournal%5D)">Small molecule inhibitors against PD-1/PD-L1 immune checkpoints and current methodologies for their development: A review.</a> Cancer Cell Int. 21 (1), 239(2021).</li>
<li>Hu, K., Li, X. -J., Asmamaw, M. D., Shi, X. -J., Liu, H. -M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Establishment+of+high-throughput+screening+HTRF+assay+for+identification+small+molecule+inhibitors+of+Skp2-Cks1%5BTitle%5D)+AND+%22Sci+Rep%22%5BJournal%5D)">Establishment of high-throughput screening HTRF assay for identification small molecule inhibitors of Skp2-Cks1.</a> Sci Rep. 11 (1), 21105(2021).</li>
<li>Puopolo, T., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Establishment+of+human+PD-1%2FPD-L1+blockade+assay+based+on+surface+plasmon+resonance+%28SPR%29+biosensor%5BTitle%5D)+AND+%22Bio-protoc%22%5BJournal%5D)">Establishment of human PD-1/PD-L1 blockade assay based on surface plasmon resonance (SPR) biosensor.</a> Bio-protoc. 13 (15), e4765(2023).</li>
<li>Ding, M., Chen, Y., Lang, Y., Cui, L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+role+of+cellular+prion+protein+in+cancer+biology%3A+A+potential+therapeutic+target%5BTitle%5D)+AND+%22Front+Oncol%22%5BJournal%5D)">The role of cellular prion protein in cancer biology: A potential therapeutic target.</a> Front Oncol. 11, 742949(2021).</li>
<li>Li, H., Seeram, N. P., Liu, C., Ma, H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Further+investigation+of+blockade+effects+and+binding+affinities+of+selected+natural+compounds+to+immune+checkpoint+PD-1%2FPD-L1%5BTitle%5D)+AND+%22Front+Oncol%22%5BJournal%5D)">Further investigation of blockade effects and binding affinities of selected natural compounds to immune checkpoint PD-1/PD-L1.</a> Front Oncol. 12, 995461(2022).</li>
<li>Kamrani, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((New+immunotherapeutic+approaches+for+cancer+treatment%5BTitle%5D)+AND+%22Pathol+Res+Pract%22%5BJournal%5D)">New immunotherapeutic approaches for cancer treatment.</a> Pathol Res Pract. 248, 154632(2023).</li>
<li>Yan, Y., Zhang, L., Zuo, Y., Qian, H., Liu, C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Immune+checkpoint+blockade+in+cancer+immunotherapy%3A+mechanisms%2C+clinical+outcomes%2C+and+safety+profiles+of+PD-1%2FPD-L1+inhibitors%5BTitle%5D)+AND+%22Arch+Immunol+Ther+Exp%22%5BJournal%5D)">Immune checkpoint blockade in cancer immunotherapy: mechanisms, clinical outcomes, and safety profiles of PD-1/PD-L1 inhibitors.</a> Arch Immunol Ther Exp. 68 (6), 36(2020).</li>
<li>Chandrasekharan, G., Unnikrishnan, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((High+throughput+methods+to+study+protein-protein+interactions+during+host-pathogen+interactions%5BTitle%5D)+AND+%22Eur+J+Cell+Biol%22%5BJournal%5D)">High throughput methods to study protein-protein interactions during host-pathogen interactions.</a> Eur J Cell Biol. 103 (2), 151393(2024).</li>
<li>Zhang, Y., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((BMS-202%2C+a+PD-1%2FPD-L1+inhibitor%2C+decelerates+the+profibrotic+effects+of+fibroblasts+derived+from+scar+tissues+via+ERK+and+TGF%CE%B21%2FSmad+signaling+pathways%5BTitle%5D)+AND+%22Immun+Inflamm+Dis%22%5BJournal%5D)">BMS-202, a PD-1/PD-L1 inhibitor, decelerates the profibrotic effects of fibroblasts derived from scar tissues via ERK and TGFβ1/Smad signaling pathways.</a> Immun Inflamm Dis. 10 (1), e591(2022).</li>
<li>Surmiak, E., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((PD-L1+inhibitors%3A+Different+classes%2C+activities%2C+and+mechanisms+of+action%5BTitle%5D)+AND+%22Int+J+Mol+Sci%22%5BJournal%5D)">PD-L1 inhibitors: Different classes, activities, and mechanisms of action.</a> Int J Mol Sci. 22 (21), 11797(2021).</li>
<li>Feoli, A., Sarno, G., Castellano, S., Sbardella, G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((DMSO-Related+effects+on+ligand-binding+properties+of+lysine+methyltransferases+G9a+and+SETD8%5BTitle%5D)+AND+%22ChemBioChem%22%5BJournal%5D)">DMSO-Related effects on ligand-binding properties of lysine methyltransferases G9a and SETD8.</a> ChemBioChem. 25 (4), e202300809(2024).</li>
<li>Tjernberg, A., Markova, N., Griffiths, W. J., HalléN, D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((DMSO-Related+effects+in+protein+characterization%5BTitle%5D)+AND+%22SLAS+Discov%22%5BJournal%5D)">DMSO-Related effects in protein characterization.</a> SLAS Discov. 11 (2), 131-137 (2006).</li>
</ol>

<table><tbody><tr><td>50 mM NaOH</td><td>Cytiva Life Sciences</td><td>100358</td><td></td></tr><tr><td>50 mM NaOH</td><td>Fisher Scientific</td><td>905376</td><td></td></tr><tr><td>96-Well Polystyrene Microplates</td><td>Cytiva Life Sciences</td><td>BR100503</td><td></td></tr><tr><td>Amine Coupling Kit</td><td>Cytiva Life Sciences</td><td>35120</td><td></td></tr><tr><td>Biacore T200 SPR System and Evaluation Software 3.2</td><td>Cytiva Life Sciences</td><td>28975001</td><td></td></tr><tr><td>Biotinylated Human PD-1 Fc, Avitag Protein</td><td>Acro Biosystems</td><td>PD1-H82F1</td><td></td></tr><tr><td>BMS1166</td><td>MedChemExpress</td><td>HY-102011</td><td></td></tr><tr><td>Dimethyl Sulfoxide (DMSO)</td><td>Sigma-Aldrich</td><td>276855</td><td></td></tr><tr><td>DNase Free Water</td><td>Fisher Scientific</td><td>188506</td><td></td></tr><tr><td>Glycine 1.5</td><td>Cytiva Life Sciences</td><td>BR100354</td><td></td></tr><tr><td>Glycine 2.0</td><td>Cytiva Life Sciences</td><td>BR100355</td><td></td></tr><tr><td>Glycine 2.5</td><td>Cytiva Life Sciences</td><td>BR100356</td><td></td></tr><tr><td>Glycine 3.0</td><td>Cytiva Life Sciences</td><td>BR100357</td><td></td></tr><tr><td>HBS-EP+ Buffer</td><td>Cytiva Life Sciences</td><td>BR100669</td><td></td></tr><tr><td>Human PD-L1 Fc Tag Protein</td><td>Acro Biosystems</td><td>PD-1-H5258</td><td></td></tr><tr><td>Isopropanol</td><td>Fisher Scientific</td><td>BP2618-1</td><td></td></tr><tr><td>Microplate Foil, 96-Well&nbsp;</td><td>Cytiva Life Sciences</td><td>28975816</td><td></td></tr><tr><td>NaCl</td><td>Sigma-Aldrich</td><td>746398</td><td></td></tr><tr><td>Plastic Vials 7 mm</td><td>Cytiva Life Sciences</td><td>BR100212</td><td></td></tr><tr><td>Rubber Caps, Type 3</td><td>Cytiva Life Sciences</td><td>BR100502</td><td></td></tr><tr><td>Series S Sensor Chip CM5</td><td>Cytiva Life Sciences</td><td>29149603</td><td></td></tr><tr><td>Sodium Acetate 4.5</td><td>Cytiva Life Sciences</td><td>100350</td><td></td></tr><tr><td>Sodium Acetate 5.0</td><td>Cytiva Life Sciences</td><td>100351</td><td></td></tr><tr><td>Streptavidin</td><td>Sigma-Aldrich</td><td>S4762</td><td></td></tr></tbody></table>

identificatie van pd-1/pd-l1-remmers met surface plasmon resonance-technologie

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identificatie van PD-1/PD-L1-remmers met Surface Plasmon Resonance-technologie

The disruption of the PD-1/PD-L1 interaction is a promising strategy for cancer immunotherapy. Reliable screening platforms are essential for evaluating ...

identifying-pd-1pd-l1-inhibitors-with-surface-plasmon-resonance

Research

JoVE Journal

Cancer Research

Kankeronderzoek

This video describes the surface plasmon resonance, or SPR, technique for studying the interaction between two molecules using a sensor chip. The change in resonance angle and the intensity of the reflected light are detected as a function of the association and dissociation of two molecules, and this provides information about the interactions between the two molecules.

Surface Plasmon Resonance to Study Biomolecular Interactions Using a Sensor Chip

This video demonstrates localized surface plasmon resonance imaging to detect protein secretions from a single cell. Using a microfluidic setup and a peptide-bound plasmonic nanostructure chip, changes in reflected light intensity at the resonance angle reveal interactions with secreted proteins from a single cell.

Localized Surface Plasmon Resonance Imaging to Detect Protein Secretions from a Single Cell

Surface Plasmon Resonance (SPR) is een label vrij werkwijze voor het detecteren van biomoleculaire interacties in real time. Hierin, een protocol voor een membraaneiwit: wordt receptor interactie experiment beschreven, terwijl de discussie over de voors en tegens van de techniek.

Real Time Metingen van membraaneiwit: Receptor Interacties gebruik Surface Plasmon Resonance (SPR)

Intercellulaire communicatie kritisch om diverse fysiologische activiteiten binnen en buiten de cel. Dit document beschrijft een protocol voor het meten van de ruimtelijke en temporele karakter van enkele cel afscheidingen. Om dit te bereiken, is een multidisciplinaire aanpak waarin label-free nanoplasmonic sensing met live-cell imaging integreert.

A-Label gratis Techniek voor de ruimte en tijd Imaging van Single Cell afscheiding

Dit werk beschrijft een nanoimprinting lithografie methode om kwalitatief hoogwaardige sensing matrices die op het principe van buitengewone optische transmissie werken. De biosensor is lage kosten, robuust, makkelijk te gebruiken, en kan detecteren cardiale troponine ik in serum op klinisch relevante concentraties (99th percentiel cutoff ∼10-400 pg/mL, afhankelijk van de test).

Met behulp van buitengewone optische transmissie te kwantificeren cardiale Biomarkers in menselijk Serum

Hier presenteren we een protocol voor co-immunoprecipitation en een op-kraal enzymatische activiteit assay gelijktijdig het bestuderen van de bijdrage van specifieke proteïne domeinen van plasmamembraan receptoren aan zowel de enzym werving en de enzymactiviteit.

Co-immunoprecipitation Assay voor het bestuderen van functionele interacties tussen receptoren en enzymen

Dit artikel stelt een nieuwe generatie multiparametrische analytische platforms voor met een verhoogde doorvoer voor de karakterisering van extracellulaire vesikelsubsets. De methode is gebaseerd op een combinatie van multiplexed biosensing-methoden met metrologische en morfomechanische analyses door atomaire krachtmicroscopie, gekoppeld aan Raman-spectroscopie, om vesiculaire doelen te kwalificeren die vastzitten op een microarray-biochip.

Multimodaal analytisch platform op een multiplexed surface plasmon resonance imaging chip voor de analyse van extracellulaire vesikel subsets

Deze studie ontwikkelde een niet-invasieve en real-time methode om de verdeling van geprogrammeerde dood-ligand 1 in het hele lichaam te evalueren, gebaseerd op positronemissie-tomografische beeldvorming van [68Ga] D-dodecapeptide-antagonist. Deze techniek heeft voordelen ten opzichte van conventionele immunohistochemie en verbetert de efficiëntie van het identificeren van geschikte patiënten die baat zullen hebben bij immuuncheckpointblokkadetherapie.

Ontwikkeling van een 68gallium-gelabelde D-peptide PET-tracer voor beeldvorming van geprogrammeerde dood-ligand 1-expressie

Checkpointremmers zijn belangrijke doelwitten bij het ontwikkelen van therapieën voor de strijd tegen kanker. Dit rapport introduceert een nieuw PDL1-peptide-gebaseerd kankervaccin, PDL1-Vaxx, dat neutraliserende polyklonale antilichaamproductie induceert die de vorming van PD-1/PDL1-complex blokkeert. Dit werk beschrijft ook de ontwikkeling en het testen van een op fluorescerende kralen gebaseerde test voor het analyseren van deze activiteit.

Magnetische fluorescerende kralen-gebaseerde dual-reporter flow-analyse van PDL1-Vaxx peptidevaccin-geïnduceerde antilichaamblokkade van de PD-1/PD-L1-interactie

Dit protocol beschrijft de aanpasbare oppervlaktefunctionalisering van het desthiobiotine, streptavidine en APTES systeem om specifieke celtypen van belang te isoleren. Daarnaast behandelt dit manuscript de toepassingen, optimalisatie en verificatie van dit proces.

Een werkwijze van gerichte Cell Isolation via Glasoppervlak functionalisering

Leer een blokkeringsassay voor PD-1/PD-L1-remmers met surface plasmon resonance-technologie. Deze methode ondersteunt high-throughput screening voor kankerimmunotherapie en versnelt de ontdekking van nieuwe geneesmiddelen.

Identificatie van PD-1/PD-L1-remmers met Surface Plasmon Resonance-technologie

Meer video's verkennen